3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Melanoma
17
Colorectal Neoplasms
15
Colonic Neoplasms
8
Carcinoma, Non-Small-Cell Lung
5
Brain Neoplasms
5
Skin Neoplasms
4
Rectal Neoplasms
4
Neoplasms
4
Lung Neoplasms
3
Neoplasm Metastasis
2
Gastrointestinal Neoplasms
2
Digestive System Neoplasms
2
Thyroid Neoplasms
1
Solid Tumors
1
Skin Diseases
1
Rectal Diseases
1
Pancreatic Neoplasms
1
Neurofibromatosis 1
1
Lymphatic Metastasis
1
Leukemia, Hairy Cell
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Hereditary Sensory and Autonomic Neuropathies
1
Gastrointestinal Diseases
1
Disease Progression
1
Digestive System Diseases
1
Colonic Diseases
1
Biliary Tract Neoplasms
1
Interventions
Aminolevulinic Acid
2
palbociclib
1
encorafenib
1
binimetinib
1
Vemurafenib
1
Sodium Chloride
1
Radiotherapy
1
Radiation
1
Injections, Intradermal
1
Gonadotropin-Releasing Hormone
1
Anastrozole
1
AZD9833
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Skin Diseases
×
encorafenib
×
1 year
×
Clear all
NCT01909453
2026-02-27
COLUMBUS
Pfizer
Phase 3
Completed
921 enrolled
48 charts
1 FDA